top of page
Decoding Neurological Disease. Building Medicines.
CELLTIUM is developing precision therapies for CMT1A and related neurological disorders. By combining deep disease biology with the proprietary PRECISION™ platform, we are advancing a translational approach that brings meaningful new treatment options closer to patients.
A New Model for Neurotherapeutics
Through the PRECISION™ platform, we integrate quantitative phenotyping, multimodal biological data, and AI into a unified discovery framework to accelerate target identification, lead optimization, and translational decision-making.
Targeting the Core Biology
We are advancing a portfolio of mechanistically distinct small-molecule therapies for CMT1A and related neuropathies, designed to address the underlying disease biology, restore peripheral nerve function, and move beyond symptom management.
Partner With Us
We welcome partnerships with investors and pharmaceutical companies to advance our CMT1A programs into the clinic and expand the PRECISION™ platform across additional neurological indications.
bottom of page